• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Mologen (Group)

MOLOGEN AG, a German biopharmaceutical company with headquarters in Berlin specializes in the research and development of innovative medications on the basis of DNA structures. The activities focus on numerous product developments which are relevant to the immune system; on the one hand vaccines against infectious diseases and on the other hand cancer medications. MOLOGEN AG is globally one of the few biotechnology companies with well tolerated DNA-based cancer treatment in the clinical development phase. The stocks of MOLOGEN AG are listed in the Prime Standard of the German stock exchange (ISIN DE0006637200). *

 

	Start	1997-01-01 existent
	Industry	BIOTECH
	Industry 2	MIDGE® technology (Mologen)
	Person	Faus, Ignacio (Mologen 201808– CEO former CEO + Co-Founder of Palau Pharma)
	Person 2	Miller, Walter (Mologen 201604– CFO before Nuvisan Gmbh + Santhera Pharmaceuticals)
	Region	Berlin
	Country	Germany
	Street	30 Fabeckstr.
	City	14195 Berlin
	Tel	+49-30-841788-0
		Address record changed: 2018-07-24
Basic data	Employees	C: 51 to 100 (2017-12-31)
	Currency	EUR
	Annual sales	47,000 (revenues (2017) 2017-12-31)
	Profit	-19,281,000 (2017-12-31)
	Cash	8,061,000 (2017-12-31)
		* Document for �About Section�: Mologen AG. (7/10/12). "Press Release: Mologen AG Capital Increase. Proceeds of 22 Million EUR".
		Record changed: 2018-08-01

Advertisement

More documents for Mologen (Group)

• [1] Mologen AG. (1/17/19). "Press Release: Full Placement of Convertible Bond 2019/2027. Total Amount Issued: EUR2.7 Million, Maturity of 8 Years, Coupon of 6% p.a. [NOT FOR US, CA, JP, et al.]". Berlin....
• [2] Mologen AG. (11/16/18). "Press Release: Mologen AG to Retain Rights to Lefitolimod – Termination of Negotiations with Oncologie Inc. and Assessment of All Strategic Options in the Light of a Likely Read-out of the Pivotal Phase III IMPALA Trial in 2019"....
• [3] Mologen AG. (11/12/18). "Press Release: Lefitolimod – First Clinical Data in Combination with a Checkpoint Inhibitor and further Preclinical Results Presented at SITC 2018". Berlin....
• [4] Convert Pharmaceuticals S.A.. (11/8/18). "Press Release: Convert Pharmaceuticals Appoints Mariola Söhngen as New CEO"....
• [5] Mologen AG. (11/8/18). "Press Release: Implementation of Financing Measures and Publication of Study Results". Berlin....
• [6] Mologen AG. (9/27/18). "Press Release: Mologen AG Completes Capital Increase with Gross Proceeds of around EUR8 Million [NOT FOR RELEASE IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN, et al.]". Berlin....
• [7] Mologen AG. (8/16/18). "Press Release: Mologen and Oncologie. Global Assignment and Co-development Agreement Relating to Mologen’s Lead Compound Lefitolimod". Berlin....
• [8] Mologen AG. (8/9/18). "Press Release: Mologen AG with Positive Developments in the First Half of 2018. Successful Financing Measures and Continuation of Clinical Studies"....
• [9] Mologen AG. (8/1/18). "Press Release: Dr Ignacio Faus Appointed as New CEO of Mologen AG". Berlin....
• [10] Mologen AG. (7/17/18). "Press Release: Resolved Reverse Share Split Implemented [NOT FOR UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH UNLAWFUL]"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Contact  |  The use of this website requires to accept the disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.